...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Mixed chimerism of bone marrow CD34+ progenitor cells (genotyping, bcr/abl analysis) after allogeneic transplantation for chronic myelogenous leukemia.
【24h】

Mixed chimerism of bone marrow CD34+ progenitor cells (genotyping, bcr/abl analysis) after allogeneic transplantation for chronic myelogenous leukemia.

机译:同种异体移植后慢性骨髓性白血病的骨髓CD34 +祖细胞混合嵌合(基因分型,bcr / abl分析)。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND Although CD34 progenitors play a crucial role during bone marrow transplantation (BMT), there is only scant knowledge concerning their lineage-restricted mixed chimerism (MCh).METHODS An immunohistochemical and fluorescence in situ hybridization study was performed on bone marrow biopsies derived from 11 patients with chronic myelogenous leukemia after sex-mismatched BMT to quantify the CD34 cell population and their expression. After proper identification by a lineage-specific monoclonal antibody, X chromosome- and Y chromosome-specific probes were used for sex typing and for labeling of the locus commercially available detection systems were applied.RESULTS After successful engraftment, 241 progenitor cells were identified at days 9 to 586 of the posttransplant period. Overall incidence of MCh was 24% with a tendency to decline after day 100 to 15%. The gene was detectable in only 10% of these precursors and decreased to less than 4% after more than 6 months. Approximately 0.5 to 5.5 years after BMT in six patients, a manifest leukemic relapse occurred, which was accompanied by a conversion of donor-to-host-type progenitors. This phenomenon involved up to 94% of the 303 evaluable CD34 cells and also included a retrieval of the translocation gene in approximately 50% of this population.CONCLUSION The lineage-restricted MCh of progenitors after BMT is in keeping with the assumption that leukemic (bcr/abl ) precursors represent only a fraction of the total host-derived (chimeric) CD34 cells. These residual clonally transformed progenitors survive myeloablative treatment and thus may be the source for a later relapse.
机译:背景技术尽管CD34祖细胞在骨髓移植(BMT)中起着至关重要的作用,但对它们的谱系限制性混合嵌合体(MCh)知之甚少。方法对11种骨髓活检组织进行了免疫组织化学和荧光原位杂交研究。性别不匹配的BMT后患有慢性粒细胞性白血病的患者,以量化CD34细胞群体及其表达。在通过谱系特异性单克隆抗体正确鉴定后,将X染色体和Y染色体特异性探针用于性别分型和标记基因座,使用市售检测系统。结果成功植入后,在第几天就鉴定出241个祖细胞移植后的9到586。 MCh的总发生率为24%,在第100天后有下降的趋势,降至15%。该基因仅在这些前体的10%中可检测到,并在超过6个月后降至4%以下。 BMT后约0.5至5.5年,有6位患者发生了明显的白血病复发,并伴有供体型向宿主型祖细胞的转化。这一现象涉及多达303个可评估CD34细胞中的94%,并且还包括在该人群中约50%的种群中恢复了易位基因。结论结论BMT后祖细胞的MCh受谱系限制符合白血病(bcr / abl)前体仅占宿主衍生(嵌合)CD34细胞总数的一小部分。这些残留的无性系转化的祖细胞在清髓治疗中幸存下来,因此可能成为以后复发的来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号